98 / 144
378
[REV. MED. CLIN. CONDES - 2016; 27(3) 363-379]
4):S13-20; discussion S1-3.
76. Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor
complications in Parkinson’s disease: an argument
for continuous drug delivery? J Neural Transm.
2013;120(9):1305-20.
77. Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al.
Extended-release carbidopa-levodopa (IPX066) compared
with immediate-release carbidopa-levodopa in patients
with Parkinson’s disease and motor fluctuations: a
phase 3 randomised, double-blind trial. Lancet Neurol.
2013;12(4):346-56.
78. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren
K, Carter JH, et al. Effect of peripheral catechol-O-
methyltransferase inhibition on the pharmacokinetics and
pharmacodynamics of levodopa in parkinsonian patients.
Neurology. 1994;44(5):913-9.
79. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi
F, et al. Rasagiline as an adjunct to levodopa in patients
with Parkinson’s disease and motor fluctuations (LARGO,
Lasting effect in Adjunct therapy with Rasagiline Given
Once daily, study): a randomised, double-blind, parallel-
group trial. Lancet. 2005;365(9463):947-54.
80. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH,
Chirilineau D, et al. Two-year, randomized, controlled
study of safinamide as add-on to levodopa in mid to late
Parkinson’s disease. Movement disorders : official journal of
the Movement Disorder Society. 2014;29(10):1273-80.
81. Swope DM. Rapid treatment of “wearing off” in Parkinson’s
disease. Neurology. 2004;62(6 Suppl 4):S27-31.
82. Pahwa R, Koller WC, Trosch RM, Sherry JH. Subcutaneous
apomorphine in patients with advanced Parkinson’s disease:
a dose-escalation study with randomized, double-blind,
placebo-controlled crossover evaluation of a single dose. J
Neurol Sci. 2007;258(1-2):137-43.
83. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro Garcia
A, Alonso Frech F, Alvarez Lopez M, et al. Efficacy of long-
term continuous subcutaneous apomorphine infusion in
advanced Parkinson’s disease with motor fluctuations: a
multicenter study. Mov Disord. 2008;23(8):1130-6.
84. Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine
infusion for severe insomnia in Parkinson’s disease. Mov
Disord. 2006;21(5):727-8.
85. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM,
Chaudhuri KR. The impact of non-motor symptoms on
health-related quality of life of patients with Parkinson’s
disease. Mov Disord. 2011;26(3):399-406.
86. Christmas TJ, Kempster PA, Chapple CR, Frankel JP, Lees
AJ, Stern GM, et al. Role of subcutaneous apomorphine in
parkinsonian voiding dysfunction. Lancet. 1988;2(8626-
8627):1451-3.
87. Todd A, James CA. Apomorphine nodules in Parkinson’s
disease: best practice considerations. British journal of
community nursing. 2008;13(10):457-63.
88. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG,
Fernandez HH, et al. Continuous intrajejunal infusion of
levodopa-carbidopa intestinal gel for patients with advanced
Parkinson’s disease: a randomised, controlled, double-blind,
double-dummy study. Lancet Neurol. 2014;13(2):141-9.
89. Caceres-Redondo MT, Carrillo F, Lama MJ, Huertas-
Fernandez I, Vargas-Gonzalez L, Carballo M, et al. Long-term
levodopa/carbidopa intestinal gel in advanced Parkinson’s
disease. J Neurol. 2014;261(3):561-9.
90. Nyholm D. Duodopa(R) treatment for advanced Parkinson’s
disease: a review of efficacy and safety. Parkinsonism &
related disorders. 2012;18(8):916-29.
91. Benabid AL, Pollak P, Gervason C, Hoffmann D, Gao DM,
Hommel M, et al. Long-term suppression of tremor by
chronic stimulation of the ventral intermediate thalamic
nucleus. Lancet. 1991;337(8738):403-6.
92. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle E,
Perret JE, et al. Bilateral subthalamic nucleus stimulation for
severe Parkinson’s disease. Mov Disord. 1995;10(5):672-4.
93. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J,
Schafer H, Botzel K, et al. A randomized trial of deep-
brain stimulation for Parkinson’s disease. N Engl J Med.
2006;355(9):896-908.
94. Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell
R, et al. Deep brain stimulation plus best medical therapy
versus best medical therapy alone for advanced Parkinson’s
disease (PD SURG trial): a randomised, open-label trial.
Lancet Neurol. 2010;9(6):581-91.
95. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P,
Timmermann L, et al. Neurostimulation for Parkinson’s
disease with early motor complications. N Engl J Med.
2013;368(7):610-22.
96. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak
P, Rehncrona S, et al. Bilateral deep brain stimulation
in Parkinson’s disease: a multicentre study with 4 years
follow-up. Brain. 2005;128(Pt 10):2240-9.
97. Castrioto A, Lhommee E, Moro E, Krack P. Mood and
behavioural effects of subthalamic stimulation in
Parkinson’s disease. Lancet Neurol. 2014;13(3):287-305.
98. Odekerken VJ, Boel JA, Schmand BA, de Haan RJ, Figee
M, van den Munckhof P, et al. GPi vs STN deep brain
stimulation for Parkinson disease: Three-year follow-up.
Neurology. 2016.
99. Okun MS. Deep-brain stimulation for Parkinson’s disease.
The New England journal of medicine. 2012;367(16):1529-
38.
100.Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach
M, et al. A multicentre study on suicide outcomes following
subthalamic stimulation for Parkinson’s disease. Brain.
2008;131(Pt 10):2720-8.
101.Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C,
Xie J, et al. Non-motor dopamine withdrawal syndrome
after surgery for Parkinson’s disease: predictors and
underlying mesolimbic denervation. Brain. 2010;133(Pt
4):1111-27.